GlobeNewswire Inc | Jul 2, 2021 07:58AM EDT

July 02, 2021

LONDON and NEW YORK, July 02, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that the Forms 20-F and F-6 filed by Accustem Sciences Limited with the SEC have been declared effective, enabling the completion of the in specie distribution and spin out of Accustem Sciences Limited. These documents together can be found at www.accustem.com

Times and dates for holders of Tiziana ordinary shares (traded on the London Stock Exchange)

The timetable for the holders of Tiziana ordinary shares (traded on the London Stock Exchange) held in CREST and Certificated form is as follows:

Demerger Record Time: 7:00 a.m. on 30 October 2020 Ex-entitlement date for Accustem Shares: 2 November 2020 CREST accounts credited with Accustem Shares: 8 July 2021* Certificates for Accustem Shares for thoseshareholders by 18 July 2021holding their Tiziana Life Sciences plc incertificated form: * replacing allocation placeholders currently showing

Times and dates for holders of Tiziana ADSs (traded on the US Nasdaq Market)

The timetable for the holders of Tiziana ADSs (traded on the Nasdaq market) are subject to different corporate action timings and holders of the ADRs should also refer to the notice published today by JP Morgan, the ADR depositary bank which can be found at https://www.adr.com/drprofile/88875G101

Announcement Tiziana CUSIP: 88875G101

Corporate Action Spin Off with DR DistributionType: Spin Off Issuer Accustem Sciences LimitedName: Spin Off DR 00442Y101CUSIP: DR Distribution 1 new Accustem DR(s) issued for every 1 existing Tiziana DRRate: held on DR Record Date Tax Withholding n/aRate: DR Record Date: November 6, 2020 DR Payment Date: July 14, 2021 DR Issuance and Cancellation Books close Date: October 28, 2020 DR Issuance and Cancellation Books reopen Date: July 19, 2021 Fees: Issuance fee: $nil per DR issued

The Issuer has announced a Spin Off Distribution in the local market. Existing Tiziana DRs will continue to be valid and will not have to be exchanged for new DRs.

For further enquiries: United Kingdom:Tiziana Life Sciences plcGabriele Cerrone, +44 (0)20 7495 2379Chairman and founderUnited States:Investors:Dave Gentry, CEORedChip Companies Inc. 1-800-RED-CHIP (733-2447)or407-491-4498dave@redchip.com